AI-generated analysis. Always verify with the original filing.
ENDRA Life Sciences Inc. initiated a process to evaluate strategic alternatives, including mergers, asset sales, or business combinations, to maximize shareholder value, and engaged Lucid Capital Management and K&L Gates. On March 19, 2026, it reduced employees, expecting approximately $51,000 in pre-tax cash severance charges in Q1 2026 to extend its operational runway.
Event Type
Disclosure
Mandatory
Variant
8-K
Costs Associated with Exit or Disposal Activities. On March 25, 2026, ENDRA Life Sciences Inc. (the “Company”) announced that it has initiated a process to eval
, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or oth
Financial Statements and Exhibits Number Description 99.1 Press Release dated March 25, 2026, furnished herewith 104 Cover Page Interactive Data File (embedded